What is the efficacy of erlotinib combined with gemcitabine in the treatment of pancreatic cancer?

Erlotinib (Erlotinib) is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor developed by Genentech (now a subsidiary of Roche Group) in the United States. It was initially used to treat non-small cell lung cancer . Subsequently, research in the field of pancreatic cancer also made breakthrough progress. Gemcitabine (Gemcitabine) is a standard chemotherapy drug for pancreatic cancer, and its combination with erlotinib has been proven to bring survival benefits.

The most representative study isNCIC CTG PA.3 trial. This multicenter, double-blind, randomized controlled study enrolled 569 patients with locally advanced or metastatic pancreatic cancer and compared gemcitabine plus erlotinib with gemcitabine monotherapy. The results showed that the median overall survival of the combination treatment group was 6.24 months, which was slightly longer than the 5.91 months of the single-drug group; and the one-year survival rate increased from 17% to 23%. Although the numerical improvement is not large, because the survival baseline of pancreatic cancer is extremely low, this difference is statistically and clinically significant. It should be noted that overexpression of EGFR is common in pancreatic cancer, but its value in predicting efficacy is limited. Therefore, erlotinib + gemcitabine treatment usually does not rely on genetic testing, but is used as an empirical choice for specific patient groups.

In addition, the most common adverse reactions of combination therapy are rash and diarrhea, which require close monitoring and symptomatic treatment. Currently, NCCN and ESMO guidelines list gemcitabine combined with erlotinib as one of the options for the treatment of advanced pancreatic cancer, especially for elderly patients who are intolerant to multi-drug combination chemotherapy or those with poor physical performance. In summary, although this combination regimen has moderate efficacy, it still has clinical practical value in the field of pancreatic cancer where treatment options are scarce.

Reference materials:https://en.wikipedia.org/wiki/Erlotinib